Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer

Although ovarian cancer is a rare disease, it constitutes the fifth leading cause of cancer death among women. It is of major importance to develop new therapeutic strategies to improve survival. Combining P8-D6, a novel dual topoisomerase inhibitor with exceptional anti-tumoral properties in ovaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Flörkemeier, Inken, Hillmann, Julia S., Weimer, Jörg P., Hildebrandt, Jonas, Hedemann, Nina, Rogmans, Christoph, Dempfle, Astrid, Arnold, Norbert, Clement, Bernd, Bauerschlag, Dirk O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505822/
https://www.ncbi.nlm.nih.gov/pubmed/36142413
http://dx.doi.org/10.3390/ijms231810503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505822/
https://www.ncbi.nlm.nih.gov/pubmed/36142413
http://dx.doi.org/10.3390/ijms231810503

Ejemplares similares